Yngvild Olsen
Datos Biográficos
| ID | 6083697 |
|---|---|
| NOMBRE | Yngvild Olsen |
| NOMBRES | Yngvild |
| APELLIDO | Olsen |
| FIRMA | ÔLSEN Y |
| AFILIACIONES | Robert P. Schwartz, Jan Gryczynski, Shannon G. Mitchell, and Jerome H. Jaffe are with the Friends Research Institute, Baltimore, MD. Robert P. Schwartz and Jerome H. Jaffe are also with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore. Kevin E. O’Grady is with the Department of Psychology, University of Maryland, College Park. Joshua M. Sharfstein is with the Maryland Department of Health and Mental Hygiene, Baltimore. Gregory Warren and Yngvild Olsen are with Baltimore... |
| VERIFICADO | No |
| TOTAL DE OBRAS | 5 |
| TOTAL DE CITAS | 6 |
| TOTAL COMO AUTOR | 5 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2013 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2023 |
| ÍNDICE H | 1 |
Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
In this survey of DATA-waivered clinicians, clinician- and systems-level challenges that limit buprenorphine prescribing were observed, even among clinicians approved under the education-exempted guidelines pathway. The findings suggest that as implementation of legislation removing the DATA waiver begins, addressing these barriers could be essential to increasing buprenorphine access
How Not to Spend an Opioid Settlement
Changes in Quality of Life following Buprenorphine Treatment
Studies of substance abuse treatment outcomes that give priority to cessation of all drug use may obscure other tangible benefits of treatment that are important to patients. The aim of this study was to examine the association between changes in quality of life (QoL) and: (1) retention in treatment; and (2) opioid use as measured by self-report and urine testing. Participants were 300 African American men and women starting outpatient buprenorph…
Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009
Objectives. We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009. Methods. We conducted a longitudinal time series analysis of archival data using linear regression with the Newey–West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity. Results. Overdose deaths attributed to…
Schwartz et al. Respond
As reported in our recent article, which found an association between expansion of methadone and buprenorphine treatment and the reduction in heroin overdose deaths in Baltimore, Maryland, between 1995 and 2009, the distribution of the opioid antagonist naloxone is one of a number of public health strategies being employed in the United States and United Kingdom (among other countries) to reduce opioid overdose deaths.1–4 From 2004 through 2009, …
Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009
Objectives. We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009. Methods. We conducted a longitudinal time series analysis of archival data using linear regression with the Newey–West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity. Results. Overdose deaths attributed to…
Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009
Objectives. We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009. Methods. We conducted a longitudinal time series analysis of archival data using linear regression with the Newey–West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity. Results. Overdose deaths attributed to…
Schwartz et al. Respond
As reported in our recent article, which found an association between expansion of methadone and buprenorphine treatment and the reduction in heroin overdose deaths in Baltimore, Maryland, between 1995 and 2009, the distribution of the opioid antagonist naloxone is one of a number of public health strategies being employed in the United States and United Kingdom (among other countries) to reduce opioid overdose deaths.1–4 From 2004 through 2009, …
Changes in Quality of Life following Buprenorphine Treatment
Studies of substance abuse treatment outcomes that give priority to cessation of all drug use may obscure other tangible benefits of treatment that are important to patients. The aim of this study was to examine the association between changes in quality of life (QoL) and: (1) retention in treatment; and (2) opioid use as measured by self-report and urine testing. Participants were 300 African American men and women starting outpatient buprenorph…
How Not to Spend an Opioid Settlement
Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
In this survey of DATA-waivered clinicians, clinician- and systems-level challenges that limit buprenorphine prescribing were observed, even among clinicians approved under the education-exempted guidelines pathway. The findings suggest that as implementation of legislation removing the DATA waiver begins, addressing these barriers could be essential to increasing buprenorphine access
Medicine (5 obras) · Opioid Use Disorder Treatment (5 obras) · Internal Medicine (4 obras) · Opioid (4 obras) · Buprenorphine (3 obras) · HIV, Drug Use, Sexual Risk (3 obras) · Opioid use disorder (3 obras) · Substance Abuse Treatment and Outcomes (3 obras) · Methadone (2 obras) · Pain Management and Opioid Use (2 obras)